SCHEMBL26040858

SCHEMBL26040858

O=C1CCC(N2C(=O)c3ccc(N4CCN(CCC5CCN(c6ccc7c(c6)Sc6cc([N+](=O)[O-])cnc6N7)CC5)CC4)cc3C2=O)C(=O)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 12/20 0.47
▸ DDB1 Q16531 1/20 0.47
▸ CCNC P24863 1/20 0.43
▸ CDK8 P49336 1/20 0.43
▸ IRAK1 P51617 1/20 0.43
▸ NTRK3 Q16288 1/20 0.43
▸ HASPIN Q8TF76 1/20 0.43
▸ CDK19 Q9BWU1 1/20 0.43
▸ IRAK4 Q9NWZ3 1/20 0.43
▸ IRAK3 Q9Y616 1/20 0.43
▸ ITK Q08881 3/20 0.42
▸ IL2 P60568 1/20 0.42
▸ AR P10275 3/20 0.42
▸ BTK Q06187 2/20 0.42
▸ EGFR P00533 3/20 0.41
▸ RAF1 P04049 2/20 0.41
▸ HPGDS O60760 2/20 0.41
▸ BRD9 Q9H8M2 1/20 0.40
▸ ERBB2 P04626 1/20 0.39
▸ CDK9 P50750 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30497551 0.91 CRBN (0.56) CRBNDDB1CCNCCDK8IRAK1
SCHEMBL21820379 0.91 CRBN (0.56) CRBNDDB1CCNCCDK8IRAK1
SCHEMBL25691033 0.86 CRBN (0.54) CRBNDDB1CCNCCDK8IRAK1
SCHEMBL23117865 0.85 CRBN (0.54) CRBNDDB1CCNCCDK8IRAK1
SCHEMBL29821993 0.85 CRBN (0.54) CRBNDDB1CCNCCDK8IRAK1
SCHEMBL26040892 0.84 CRBN (0.42) CRBNDDB1ARBTKEGFR
SCHEMBL26040903 0.84 CRBN (0.42) CRBNDDB1AREGFRHPGDS
SCHEMBL23117832 0.80 CRBN (0.57) CRBNDDB1IRAK1IRAK4IRAK3
SCHEMBL25691420 0.79 CRBN (0.45) CRBNDDB1CCNCCDK8IRAK1
SCHEMBL26040838 0.79 CRBN (0.52) CRBNDDB1IRAK4EGFRBRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2023-07-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use UCHL1, ADRM1, CRBN CRBN 3/4885DDB1 434/4885CCNC 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback